JPH1087484A5 - - Google Patents

Info

Publication number
JPH1087484A5
JPH1087484A5 JP1997204344A JP20434497A JPH1087484A5 JP H1087484 A5 JPH1087484 A5 JP H1087484A5 JP 1997204344 A JP1997204344 A JP 1997204344A JP 20434497 A JP20434497 A JP 20434497A JP H1087484 A5 JPH1087484 A5 JP H1087484A5
Authority
JP
Japan
Prior art keywords
formula
compound
use according
cyano
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1997204344A
Other languages
English (en)
Japanese (ja)
Other versions
JPH1087484A (ja
Filing date
Publication date
Priority claimed from DE19640555A external-priority patent/DE19640555A1/de
Application filed filed Critical
Publication of JPH1087484A publication Critical patent/JPH1087484A/ja
Publication of JPH1087484A5 publication Critical patent/JPH1087484A5/ja
Pending legal-status Critical Current

Links

JP9204344A 1996-07-31 1997-07-30 アポプトーシスのモジュレーションのためのイソオキサゾールおよびクロトンアミド誘導体の使用 Pending JPH1087484A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19630838 1996-07-31
DE19640555A DE19640555A1 (de) 1996-10-01 1996-10-01 Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Modulation der Apoptose
DE19630838:0 1996-10-01
DE19640555:6 1996-10-01

Publications (2)

Publication Number Publication Date
JPH1087484A JPH1087484A (ja) 1998-04-07
JPH1087484A5 true JPH1087484A5 (enExample) 2005-05-19

Family

ID=26027963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9204344A Pending JPH1087484A (ja) 1996-07-31 1997-07-30 アポプトーシスのモジュレーションのためのイソオキサゾールおよびクロトンアミド誘導体の使用

Country Status (10)

Country Link
US (1) US6011051A (enExample)
EP (1) EP0821952B1 (enExample)
JP (1) JPH1087484A (enExample)
AT (1) ATE262901T1 (enExample)
AU (1) AU718728B2 (enExample)
CA (1) CA2212207C (enExample)
DE (1) DE59711463D1 (enExample)
DK (1) DK0821952T3 (enExample)
ES (1) ES2218623T3 (enExample)
PT (1) PT821952E (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
DE19860802A1 (de) * 1998-12-30 2000-10-26 Virgene Pharmaceuticals Ag Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren
WO2001021160A2 (en) * 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
CA2390857A1 (en) * 1999-11-30 2001-06-14 Fatih M. Uckun Inhibitors of collagen-induced platelet aggregation
US6458930B1 (en) 2000-11-28 2002-10-01 Cytokinetics, Inc. Aspergillus fumigatus cofilin
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
WO2003057241A1 (en) 2001-12-28 2003-07-17 Daiichi Suntory Pharma Co., Ltd. Agents promoting the proliferation and/or differentiation of hematopoietic stem cells and/or hematopoietic precursor cells
GB0224014D0 (en) * 2002-10-15 2002-11-27 Oxford Glycosciences Uk Ltd A protein involved in therapy
AP2516A (en) * 2007-05-03 2012-11-26 Pfizer Ltd 2-Pyridine carboxamide derivatives as sodium channel modulators
ES2591355T3 (es) * 2010-08-24 2016-11-28 Algiax Pharmaceuticals Gmbh Uso novedoso de leflunomida y malononitrilamidas

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
IL99811A (en) * 1990-10-30 1996-03-31 Roussel Uclaf 3-cycloalkyl-propanamides their tautomer forms and their salts preparation process and compositions containing them
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
ES2079765T3 (es) * 1991-10-23 1996-01-16 Hoechst Ag Derivados de amidas de acido n-fenil-2-ciano-3-hidroxicrotonico y su utilizacion como medicamento con propiedad inmunomoduladora.
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
DE59407412D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha
EP0607775B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
EP0607776B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
ATE174220T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von interleukin 8
TW314467B (enExample) * 1993-03-31 1997-09-01 Hoechst Ag
GB9313365D0 (en) * 1993-06-29 1993-08-11 Roussel Lab Ltd Chemical compounds
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin

Similar Documents

Publication Publication Date Title
JPH09505809A (ja) ヒドロキシカルバゾール化合物類による平滑筋移動および増殖の阻害
ES2295009T3 (es) Inhibidores de rho quinasa para la profilaxis y el tratamiento de neumonia intersticial y fibrosis pulmonar.
JP5631053B2 (ja) 門脈圧亢進症の予防及び／又は治療
JP2006515310A5 (enExample)
JP6557684B2 (ja) 線維性疾患の治療に用いられるｐｐａｒ化合物
JPH1087484A5 (enExample)
JP2002523452A (ja) 肺疾患の治療方法
JP2003519228A5 (enExample)
JP2004517843A5 (enExample)
CN104066324A (zh) 治疗痛风急性发作的方法
JP2013237683A (ja) 肺高血圧症の治療のためのロフルミラスト
CN101068571A (zh) 改善透粘膜给药制剂的吸收的方法
US20020045652A1 (en) Prophylactic or therapeutic drug for renal diseases
EP3503923A1 (en) Combination therapies for the treatment of hepatocellular carcinoma
CN1543344A (zh) 治疗尿失禁的芳基(或杂芳基)氮杂茂甲醇衍生物
JP2002534477A (ja) メラガトランの新規使用
JPH1067662A5 (enExample)
CN117940128A (zh) 异丁司特用于防止眼癌转移
JPH06506192A (ja) 阻害剤
AU2013362755A1 (en) Uses and methods for the treatment of liver diseases or conditions
JP2003501462A (ja) 受容体アゴニストおよびアンタゴニスト
CN115279367B (zh) 用于治疗细胞因子风暴和细胞因子释放综合征的组合物和方法
JPWO2004032964A1 (ja) アレルギー性疾患治療剤
CN118203565A (zh) 去甲替林治疗纤维化疾病的药物用途
JP2006528155A (ja) ３，７−ジアザビシクロ［３．３．１］ノナン化合物の、ヒト男性患者の抗不整脈事象治療及び／又は予防のための使用